If you have been reading about BDNF and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-09-26. Where a claim depends on a specific study, the study is described rather than over-claimed.
Published clinical evidence is limited. Most controlled trials were conducted in Russia, enrolled modest numbers of participants, and appeared in Russian-language journals, which restricts independent verification. Reported outcomes include lower anxiety scores, improved attention and memory measures, and changes in fatigue ratings. Reviews written in English note methodological limitations such as small samples and inconsistent endpoints. Whether the compound produces clinically meaningful benefit relative to established anxiolytics is therefore an open question rather than an established finding.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. It was designed at the Institute of Molecular Genetics of the Russian Academy of Sciences as a structural analogue of tuftsin, a naturally occurring tetrapeptide fragment of the immunoglobulin heavy chain. The added Pro-Gly-Pro tail was intended to slow enzymatic degradation and extend biological activity. In Russia it is registered as an anxiolytic nasal preparation, while regulators elsewhere have not approved it for clinical use.
Proposed mechanisms centre on modulation of the GABAergic system, with reports of altered expression of genes related to GABA-A receptor subunits and changed monoamine turnover. Some studies describe inhibition of enkephalinase, the enzyme that degrades endogenous enkephalins, which may prolong opioid peptide signalling. Effects on brain-derived neurotrophic factor and on cytokine expression have also been reported. These findings come largely from animal models and small human studies, and the precise primary target remains unresolved.
Naming for this compound is not fully standardised in English sources. The spelling Selanc appears in some transliterations, and catalogue entries may instead list the peptide sequence itself as the identifier. Reference material sometimes groups it with other short synthetic peptides studied for behavioural effects, which can create confusion when citations are compared. Distinguishing the exact sequence from related tuftsin analogues is therefore a practical first step when reviewing any dataset or specification sheet.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, frequently abbreviated as TKPRPGP. It was designed as a structural analogue of tuftsin, a naturally occurring tetrapeptide released by enzymatic cleavage of the immunoglobulin heavy chain. The two additional proline residues at the C-terminal end extend the parent chain and change how the molecule behaves in solution. The free peptide has a calculated molecular mass of approximately 751.9 g/mol and is generally supplied as a lyophilised white to off-white powder.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C33H57N11O9 | Free peptide form |
| Molecular mass | About 751.9 Da | Calculated average mass |
| Amino acid sequence | Thr-Lys-Pro-Arg-Pro-Gly-Pro | Single-letter form TKPRPGP |
| Structural basis | Tuftsin analogue | Extended version of a natural tetrapeptide |
| Development origin | Russian Academy of Sciences | Work carried out from the 1980s onward |
Laboratory work relies on standard behavioral paradigms. Rodents are tested in the elevated plus maze, open field, and passive avoidance tasks, with outcomes compared against diazepam or vehicle controls. Intranasal dosing is used most often because it bypasses first-pass metabolism, though intraperitoneal and intravenous routes also appear in published protocols. Biochemical endpoints include tissue BDNF concentrations, cytokine levels, and monoamine metabolites. Human data are limited to small Russian trials reporting reduced anxiety scores; most were not prospectively registered, and few employed independent outcome assessment.
Measuring peptide exposure inside the brain is technically difficult. Selank is degraded rapidly in plasma, and assays must separate intact peptide from fragments, which favors targeted mass spectrometry over immunoassays alone. Reported half-lives are short, on the order of minutes, so effects observed hours later are attributed to downstream signaling rather than to the parent compound. Blood-brain barrier permeability is debated and rarely quantified directly. Gaps include absent dose-response characterization, inconsistent reporting of purity, and almost no pharmacokinetic data from human participants.
Selank is studied chiefly as an animal-model anxiolytic with proposed secondary effects on memory and immune signaling. Reported mechanisms include modulation of the GABA-A receptor complex, inhibition of enkephalin-degrading enzymes, and shifts in monoamine turnover within limbic structures. Some experiments describe increased expression of brain-derived neurotrophic factor in the hippocampus after repeated dosing. No single molecular target has been confirmed, and the peptide does not bind any receptor with the selectivity typical of a conventional small-molecule drug. Mechanism therefore remains a set of hypotheses rather than an established pathway.
Reported pharmacological effects center on reduced anxiety-like behavior in animal models and on measures of memory and learning. Proposed contributing mechanisms include modulation of GABAergic signaling, shifts in monoamine turnover, and changes in the activity of enzymes that degrade neuropeptides. Effects on the expression of genes linked to neuroplasticity have also been described. No single molecular target is widely accepted, and whether the behavioral findings arise from one pathway or several remains an open question.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. It was designed as a stabilized analogue of tuftsin, a naturally occurring tetrapeptide fragment derived from the immunoglobulin heavy chain. The additional Pro-Gly-Pro segment at the carboxyl terminus is intended to slow enzymatic cleavage. The compound is usually described in the literature as a synthetic peptide with anxiolytic and cognitive-related activity, a label that reflects a research context rather than an approved therapeutic category.
Due to the reliance on most principles of the basic science of Biochemistry, early contemporary physicians were informally qualified to perform research on their own in mainly this (today also related biomedical sciences) field.
Dietary proteins are digested into amino acids to replenish the body's free amino acid pool, which is mostly used to make new body proteins, but is also critically important for energy production and to make other vital nitrogen-containing molecules.
=== 1993 to 2011 list of genera === Following Taylor et al., from 1993 to 2011, the family Conidae was defined as including not only the cone snails, but also a large number of other genera which are commonly known as "turrids". However, as a result of molecular phylogeny studies in 2011, many of those genera were moved back to the Turridae, or were placed in new "turrid" families within the superfamily Conoidea. The following list of genera that used to be included in Conidae is retained as a historical reference:
In October, a two-day demonstration in Reggio by some 40,000 northern CGIL metalworkers, supported the revolt. The Reggio revolt was one of the most controversial periods in the history of Calabria, partly because of the absence of related documentation, which was often destroyed or hidden. Historiography generally reflects the perspective of the author. Examples:
== Development history == Bimagrumab was developed by Novartis, in collaboration with Morphosys. On August 20, 2013, it was announced that bimagrumab had received a breakthrough therapy designation for sporadic inclusion body myositis (sIBM) by the US Food and Drug Administration (FDA). In 2014, Bimagrumab entered Phase II development, with some research indicating clinical effects. Novartis planned to apply in 2016 for FDA approval to treat sIBM patients with bimagrumab. In April 2016, Novartis announced that bimagrumab had failed a Phase IIb/III study for sporadic inclusion body myositis. In January 2021, a new study confirmed that treatment with bimagrumab is safe and effective for treating excess adiposity and metabolic disturbances of adult patients with obesity and type 2 diabetes. Novartis then licensed the drug to Versanis Bio, a Medicxi Fund and Atlas Venture-backed startup, who closed a series A financing round to fund a phase II clinical program targeting weight loss in obese patients. In January 2023 Versanis Bio entered the medication into phase IIb trials for obesity. In July 2023, Eli Lilly bought Versanis Bio for their weight loss asset for $1.9 billion. In 2025, a phase IIb study was concluded testing bimagrumab in combination with Novo Nordisk's semaglutide, demonstrating that the combination resulted in a greater loss of fat as a percentage of weight compared to semaglutide alone. In September 2025, Eli Lilly terminated a phase IIb study investigating a tirzepatide-bimagrumab combination in obese and type II diabetic patients.
Sources: en.wikipedia.org
Zinc is an efficient Lewis acid, making it a useful catalytic agent in hydroxylation and other enzymatic reactions. The metal also has a flexible coordination geometry, which allows proteins using it to rapidly shift conformations to perform biological reactions. Two examples of zinc-containing enzymes are carbonic anhydrase and carboxypeptidase, which are vital to the processes of carbon dioxide (CO2) regulation and digestion of proteins, respectively. In vertebrate blood, carbonic anhydrase converts CO2 into bicarbonate and the same enzyme transforms the bicarbonate back into CO2 for exhalation through the lungs. Without this enzyme, this conversion would occur about one million times slower at the normal blood pH of 7 or would require a pH of 10 or more. The non-related β-carbonic anhydrase is required in plants for leaf formation, the synthesis of indole acetic acid (auxin) and alcoholic fermentation. Carboxypeptidase cleaves peptide linkages during digestion of proteins. A coordinate covalent bond is formed between the terminal peptide and a C=O group attached to zinc, which gives the carbon a positive charge. This helps to create a hydrophobic pocket on the enzyme near the zinc, which attracts the non-polar part of the protein being digested.
== Effects of lack of CCAP == There have been no mutant individuals of any species found to possess CCAP who have a genetic defect meaning they are not able to produce the peptide. It is likely any such mutation would be lethal. In Drosophila the destruction of CCAP-containing neurons during development causes major changes in and disruptions to timing and behaviour of moulting.
Fibrodysplasia ossificans progressiva (; abbr. FOP), also called Münchmeyer disease or formerly myositis ossificans progressiva, is an extremely rare connective tissue disease. Fibrous connective tissue such as muscle, tendons, and ligaments ossify into bone tissue. The condition ultimately immobilises sufferers, as new bone replaces musculature and fuses with the existing skeleton. This has earned FOP the nickname "stone man disease". FOP is caused by a mutation of the gene ACVR1, affecting the body's repair mechanism. Fibrous tissue, including muscle, tendons, and ligaments ossify, either spontaneously or when damaged by trauma. In many cases, otherwise minor injuries can cause joints to permanently fuse as new bone forms, replacing the damaged muscle tissue. This new bone formation (known as "heterotopic ossification") eventually forms a secondary skeleton progressively restricting the patient's ability to move. Circumstantial evidence suggests that the disease can cause joint degradation separate from its characteristic bone growth. It is a severe, debilitating disorder. Bone formed as a result of ossification is identical to "normal" bone, but in improper locations. The rate of ossified bone growth varies by patient. It is the only known medical condition in which tissue of one organ system changes into that of another. Surgical removal of ossified bone causes the body to "repair" the affected area with additional bone. FOP has no current known cure. However, there are intermittent treatments such as anti-inflammatory drugs.
It was agreed to by a previous Progressive Conservative government after DynaLIFE appealed AHS's contractual arrangement for provision of lab services with Sonic Healthcare, an Australian company. Sonic would have provided these services in Edmonton and northern Alberta starting in October 2014, but the contract was cancelled through DynaLIFE's successful appeal. The provincial government announced on December 5, 2022, that the public Alberta Precision Laboratories (APL) was going to be replaced by the private, for-profit DynaLIFE in providing community lab services in Alberta's large municipalities. By early January 2023, wait times had increased for blood tests that used to be routine and rapid. A University of Calgary assistant professor in health law questioned DynaLIFE's cut backs on "staffing or hours".
Sources: en.wikipedia.org
It is a seven-amino-acid peptide, Thr-Lys-Pro-Arg-Pro-Gly-Pro, produced by chemical synthesis rather than extracted from biological tissue. Its design is based on tuftsin, a natural immunomodulatory tetrapeptide. The C-terminal Pro-Gly-Pro segment is a common stabilising motif in short regulatory peptides.
The core four residues correspond to tuftsin, which occurs naturally as part of immunoglobulin G. The full seven-residue sequence, however, is not a known endogenous peptide. It is a laboratory-designed analogue intended to combine tuftsin-like activity with greater resistance to breakdown.
No single receptor has been confirmed as the primary target. Reports describe involvement of the GABAergic system, interference with enkephalin degradation, and shifts in neurotrophic factor expression. Because these observations come from different models and assays, they have not yet been integrated into one accepted mechanism.
The sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro, commonly written as TKPRPGP. It shares the first four residues with tuftsin and carries three prolines in the chain. The proline-rich tail is the main structural feature that separates it from the parent tetrapeptide.